Table 1.
Published patients with CVT treated with DOAC
| Study | Year | Location | Anticoagulant | N | Study type |
| Bando et al43 | 2020 | Japan | Edoxaban | 1 | Case report |
| Hsu et al24 | 2020 | USA | Rivaroxaban Apixaban |
1 7 |
Observational cohort |
| Saito et al44 | 2020 | Japan | Edoxaban | 1 | Case report |
| Sugiyama et al45 | 2020 | Japan | Edoxaban | 1 | Case report |
| Chiu et al39 | 2020 | USA | Dabigatran | 1 | Case report |
| Powell et al25 | 2020 | USA | Rivaroxaban Apixaban |
12 7 |
Observational cohort |
| Bolaji et al46 | 2020 | UK | Edoxaban | 1 | Case report |
| Ferro et al23 | 2019 | Multicentre | Dabigatran | 60 | Randomised controlled trial |
| Lurkin et al26 | 2019 | France | Dabigatran Rivaroxaban Apixaban |
2 13 1 |
Observational cohort |
| Wasay et al27 | 2019 | Multicentre | Rivaroxaban Dabigatran |
36 9 |
Observational cohort |
| Huang et al37 | 2019 | China | Dabigatran | 1 | Case report |
| Covut et al29 | 2019 | USA | Rivaroxaban Apixaban |
4 5 |
Case series |
| Hu et al38 | 2019 | China | Dabigatran | 1 | Case report |
| Rusin et al31 | 2019 | Poland | Dabigatran Rivaroxaban Apixaban |
18 10 8 |
Case series |
| Shankar Iyer et al30 | 2018 | India | Rivaroxaban | 20 | Case series |
| Yasushi42 | 2017 | Japan | Edoxaban | 1 | Case report |
| Sui et al48 | 2017 | China | Rivaroxaban | 1 | Case report |
| Becerra et al52 | 2017 | Argentina | Dabigatran | 1 | Case report |
| Budhram et al51 | 2017 | Canada | Rivaroxaban | 1 | Case report |
| Cappellari et al32 | 2017 | Italy | Rivaroxaban | 4 | Case series |
| Hsu et al50 | 2017 | China | Rivaroxaban | 1 | Case report |
| Inche Mat et al55 | 2017 | Malaysia | Dabigatran | 1 | Case report |
| Rao et al41 | 2017 | USA | Apixaban | 3 | Case report |
| Talamo et al40 | 2017 | USA | Apixaban | 1 | Case report |
| Herweh et al28 | 2016 | Germany | Rivaroxaban Apixaban |
12 1 |
Observational cohort |
| Anticoli et al34 | 2016 | Italy | Rivaroxaban | 6 | Case series |
| Cho et al49 | 2016 | South Korea | Rivaroxaban | 1 | Case report |
| Micieli et al47 | 2016 | Canada | Rivaroxaban | 1 | Case report |
| Mendonça et al33 | 2015 | Portugal | Dabigatran | 18 | Case series |
| Mutgi et al36 | 2015 | USA | Rivaroxaban | 2 | Case report |
| Sugie et al35 | 2015 | Japan | Rivaroxaban | 1 | Case report |
| Mathew et al54 | 2013 | India | Dabigatran | 1 | Case report |
| Hon et al53 | 2012 | Hong Kong | Dabigatran | 2 | Case report |
CVT, cerebral venous thrombosis; DOAC, direct oral anticoagulants.